Adult-onset Still's disease medical therapy

Jump to navigation Jump to search

Adult-onset Still's disease


Patient Information


Historical Perspective




Differentiating Adult-onset Still’s Disease from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings



Echocardiography and Ultrasound

CT scan


Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Template:Adult-onset Still's disease On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Template:Adult-onset Still's disease

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Adult-onset Still's disease medical therapy

CDC on Template:Adult-onset Still's disease

Template:Adult-onset Still's disease in the news

Blogs on Template:Adult-onset Still's disease

Risk calculators and risk factors for Template:Adult-onset Still's disease

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]


Medical therapy in adult-onset Still's disease (AOSD) is guided by disease activity and severity. Corticosteroids are the first line therapy; Disease Modifying Anti-Rheumatic Drugs (DMARDs) as monotherapy or in combination with other agents may be used in refractory or complicated cases.

Medical Therapy

Medical therapy in adult-onset Still's disease (AOSD) is guided by disease activity and severity. The following agents may be used in the management of AOSD:[1]

  • 1.1 Adults
    • Preferred regimen (1): Prednisone PO 0.8-1 mg/kg/day
  • 1.2 Adults (Steroid dependence)
  • 1.3 Adults (Refractory AOSD)
    • 1.3.1 Chronic arthritis
      • Preferred regimen (1): Infliximab IV initial 3 mg/kg at 0, 2, and 6 weeks; then 3 to 6 mg/kg/dose every 8 weeks
      • Preferred regimen (2): Tocilizumab IV  8 mg/kg
      • Alternative regimen (1): Leflunomide <20 kg: 100 mg as a single dose followed by 10 mg every other day; 20 kg to 40 kg: 100 mg once daily for 2 days followed by 10 mg once daily; >40 kg: 100 mg once daily for 3 days followed by 20 mg once daily and Azathioprine initial1 mg/kg/day (50 to 100 mg) given once daily or divided twice daily; after 6 to 8 weeks, may increase by 0.5 mg/kg every 4 weeks until response or up to 2.5 mg/kg/day; an adequate trial should be a minimum of 12 weeks
    • 1.3.2 Systemic flares
      • Preferred regimen (1): Anakinra SC initial 1 to 2 mg/kg once daily; maximum initial dose: 100 mg; if no response after 1 to 2 weeks, may titrate up to 4 mg/kg once daily (maximum: 200 mg/day)
      • Alternative regimen (1): Canakinumab  SC children ≥2 years and ≥7.5 kg and Adolescents: 4 mg/kg every 4 weeks (maximum: 300 mg per dose)
      • Alternative regimen (2): Rilonacept
  • 1.4 Adults (Complicated AOSD)


  1. Gerfaud-Valentin, Mathieu; Jamilloux, Yvan; Iwaz, Jean; Sève, Pascal (2014). "Adult-onset Still's disease". Autoimmunity Reviews. 13 (7): 708–722. doi:10.1016/j.autrev.2014.01.058. ISSN 1568-9972.

Template:WH Template:WS